Checkmate Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 31

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $250M

Checkmate Pharmaceuticals General Information

Description

Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Drug Discovery
Corporate Office
  • 245 Main Street
  • 2nd Floor
  • Cambridge, MA 02142
  • United States
+1 (978) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Checkmate Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 31-May-2022 $250M 00000 00000 Completed Generating Revenue
6. IPO 07-Aug-2020 0000 00000 00000 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 09-Jun-2020 000.00 00000 00000 Completed Generating Revenue
4. Early Stage VC (Series B) 27-Jan-2020 0000 0000 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 12-Dec-2018 0000 0000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 02-Jun-2017 $27M $52M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 16-Feb-2017 $25M $25M 0000 Completed Generating Revenue
To view Checkmate Pharmaceuticals’s complete valuation and funding history, request access »

Checkmate Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.00
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 25,000,000 $0.000100 $0.08 $1 $1 1x $1 19.06%
To view Checkmate Pharmaceuticals’s complete cap table history, request access »

Checkmate Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its pr
Biotechnology
Cambridge, MA
31 As of 2022
00000
00000 0000-00-00
000000&0 00000

000000

ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000

00000

in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000000000000
Thousand Oaks, CA
00000 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Checkmate Pharmaceuticals Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 000.00 000000000 000.00
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
Selecta Biosciences Formerly VC-backed Watertown, MA 00 00000 000000&0 00000
Dynavax Technologies Formerly VC-backed Emeryville, CA 000 00000 000000000 00000
You’re viewing 5 of 47 competitors. Get the full list »

Checkmate Pharmaceuticals Patents

Checkmate Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020372478-A1 Synthetic rig-i-like receptor agonists Pending 23-Oct-2019 00000000000
CA-3155202-A1 Synthetic rig-i-like receptor agonists Pending 23-Oct-2019 00000000000
US-20220378817-A1 Synthetic rig-i-like receptor agonists Pending 23-Oct-2019 00000000000
EP-4048795-A1 Synthetic rig-i-like receptor agonists Pending 23-Oct-2019 00000000000
US-20200063141-A1 Synthetic rig-i-like receptor agonists Active 19-Apr-2018 C12N15/117
To view Checkmate Pharmaceuticals’s complete patent history, request access »

Checkmate Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Checkmate Pharmaceuticals Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BrightEdge Impact Investing Minority 000 0000 000000 0
Clough Capital Partners Hedge Fund Minority 000 0000 000000 0
Decheng Capital Venture Capital Minority 000 0000 000000 0
Eight Roads Corporate Venture Capital Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Checkmate Pharmaceuticals FAQs

  • When was Checkmate Pharmaceuticals founded?

    Checkmate Pharmaceuticals was founded in 2015.

  • Who is the founder of Checkmate Pharmaceuticals?

    Arthur Krieg MD and Charles Yon are the founders of Checkmate Pharmaceuticals.

  • Where is Checkmate Pharmaceuticals headquartered?

    Checkmate Pharmaceuticals is headquartered in Cambridge, MA.

  • What is the size of Checkmate Pharmaceuticals?

    Checkmate Pharmaceuticals has 31 total employees.

  • What industry is Checkmate Pharmaceuticals in?

    Checkmate Pharmaceuticals’s primary industry is Biotechnology.

  • Is Checkmate Pharmaceuticals a private or public company?

    Checkmate Pharmaceuticals is a Private company.

  • What is the current valuation of Checkmate Pharmaceuticals?

    The current valuation of Checkmate Pharmaceuticals is 00000.

  • What is Checkmate Pharmaceuticals’s current revenue?

    The current revenue for Checkmate Pharmaceuticals is 000000.

  • How much funding has Checkmate Pharmaceuticals raised over time?

    Checkmate Pharmaceuticals has raised $250M.

  • Who are Checkmate Pharmaceuticals’s investors?

    BrightEdge, Clough Capital Partners, Decheng Capital, Eight Roads, and F-Prime Capital are 5 of 12 investors who have invested in Checkmate Pharmaceuticals.

  • Who are Checkmate Pharmaceuticals’s competitors?

    CytomX Therapeutics, Amgen, Inovio Pharmaceuticals, Selecta Biosciences, and Dynavax Technologies are some of the 47 competitors of Checkmate Pharmaceuticals.

  • When was Checkmate Pharmaceuticals acquired?

    Checkmate Pharmaceuticals was acquired on 31-May-2022.

  • Who acquired Checkmate Pharmaceuticals?

    Checkmate Pharmaceuticals was acquired by Regeneron Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »